Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics, Abbott Labs Ink Broad Molecular-Diagnostics Collaboration

Click here to view an updated version of this article.

NEW YORK, June 24 - Celera Diagnostics and Abbott Labs will partner to develop and market a "broad range" of in vitro molecular diagnostics to detect and monitor a variety of diseases, the companies said today.

Roughly 250 scientists and engineers from both firms will hunt markers to infectious diseases, cancer, central nervous system disorders, and cardiovascular and autoimmune diseases, the companies said.

Specifically, Celera Diagnostics will focus on discovering and validating genetic markers and developing assays while Abbott concentrates on product development, sales, and marketing, the partners said. The companies stressed they will not try to develop or commercialize proteins, immunoassays, or products for either the research or pharmaceutical markets.

Under the terms of the agreement, which reflects Celera Diagnostics' only alliance since it was formed slightly more than one year ago, the companies will share expenses and profits tied to researching, developing, manufacturing, and commercializing any products that may arise. Abbott also will distribute worldwide "most" products.

The partners agreed to share each other's technologies and patents; Abbott researchers will have access to Applied Biosystems' instruments and Celera Genomics' gene data and analytical tools, for example.  


Celera said it plans to host a conference call tomorrow at 10:00 a.m. Eastern time. Click here for more information.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.